Case Report
Copyright ©The Author(s) 2020.
World J Clin Oncol. Nov 24, 2020; 11(11): 959-967
Published online Nov 24, 2020. doi: 10.5306/wjco.v11.i11.959
Figure 2
Figure 2 Trend in carcinoembryonic antigen levels during irinotecan with oxaliplatin rechallenge therapy. CEA: Carcinoembryonic antigen; IROX: Irinotecan with oxaliplatin.